IMC Chicago’s Trevi Therapeutics TRVI Stock Holding History

IMC Chicago’s Portfolio TRVI Stock Details TRVI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$418K	Buy	+22,400	New	+$326K	﹤0.01%	4860

Other funds holding TRVI

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return

Emerald Advisers Leola, Pennsylvania $4.25B AUM 141.71% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

NFT

Nan Fung Trinity Central, Hong Kong, Hong Kong $1.01B AUM 64.38% 1-Year Est. Return

EMFAT

Emerald Mutual Fund Advisers Trust Leola, Pennsylvania $2.85B AUM 140.52% 1-Year Est. Return

FLPIM

F.L. Putnam Investment Management Lynnfield, Massachusetts $8.39B AUM 37.75% 1-Year Est. Return

PCM

Peregrine Capital Management Minneapolis, Minnesota $3.08B AUM 29.51% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

IMC Chicago's TRVI Position: Q2 2026 in Review

IMC Chicago sold out of Trevi Therapeutics (TRVI) in Q2 2026, closing a stake of 24,324 shares — an estimated $354K sold.

IMC Chicago first reported a position in TRVI in Q3 2025 and held it in 3 quarters. The position peaked at $486K in Q4 2025. 69 funds tracked by Wall St. Rank hold TRVI as of Q2 2026.

IMC Chicago reported no remaining Trevi Therapeutics position as of Q2 2026 after selling out during the quarter.
IMC Chicago sold 24,324 Trevi Therapeutics shares in Q2 2026, an estimated $354K.
IMC Chicago first reported a position in Trevi Therapeutics in Q3 2025 and held it in 3 quarters.
IMC Chicago's Trevi Therapeutics position peaked at $486K in Q4 2025.
69 funds tracked by Wall St. Rank held Trevi Therapeutics as of Q2 2026.

Based on IMC Chicago's 13F filing for Q2 2026, filed 6 Aug 2026.